Adjuvant hormone therapy is indicated only in @entity1 whose @entity5 express @entity172 or @entity1420 receptors. Aromatase inhibitors (AI) are indicated only in postmenopausal @entity1 . AI are significantly more effective than @entity440 in terms of disease-free survival and distant recurrence-free survival; these advantages will probably result in a significant overall survival benefit after sufficient follow-up. This benefit justifies the use of AI in all postmenopausal @entity1 in the absence of contraindications and after complete explanations of the benefit/risk ratio and potential side effects of this treatment. The benefit of AI over @entity440 may be particularly pronounced for @entity5 overexpressing @entity1722 and perhaps for ER+PR- @entity5 . Replacement of @entity440 by AI or first-line treatment with AI is advised in @entity1 with such @entity5 . Extended adjuvant treatment with AI for 5 years significantly increases survival among @entity1 already treated with @entity440 for 5 years; it also provides a significant overall survival benefit to @entity1 with positive axillary nodes and should be used in this group. AI may cause several generally mild side effects, including @entity22 , @entity4841 , @entity604 , @entity2133 , @entity546 and loss of libido. @entity440 may be appropriate for well-informed @entity1 with these side effects, especially those with RE+ RP+ @entity5 and a low risk of @entity1031 or endometrial complications. The effects of AI on memory and cognition should also be investigated thoroughly before its long-term use, especially in the elderly.

[Aromatase inhibitors in the adjuvant treatment of early breast cancer. Is there still a place for XXXX ?].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen', 'Tamoxifen'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity2133 :: ('MESH:D014987', 'Disease') :: ['vaginal dryness'] @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic'] @entity4841 :: ('MESH:D018771', 'Disease') :: ['arthralgia'] @entity546 :: ('MESH:D004414', 'Disease') :: ['dyspareunia'] @entity1722 :: ('2064', 'Gene') :: ['HER-2'] @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia']
@entity440 :: (MESH:D013629,Chemical) :: ['tamoxifen']
